Ulf Eriksson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ulf Eriksson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Kristian Pietras
Lund University
2 shared publications - Linda Fredriksson
Ludwig Institute for Cancer Research, Stockholm Branch, Box 240, S-171 77 Stockholm, Sweden
2 shared publications Annica Pontén
Ludwig Institute for Cancer Research, S-17177 Stockholm, Sweden
1 shared publicationChrister Betsholtz
Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Laboratory of Vascular Biology, Karolinska Institutet, Stockholm, S-171 77, Sweden
1 shared publicationChristina Fieber
Ludwig Institute for Cancer Research Stockholm Branch Box 240 S-171 77 Stockholm Sweden
1 shared publication- Daniel A. Lawrence
University of Michigan Medical School
1 shared publication
Latest Publications
- Top Cited Papers
- 22 June 2008
- Published by Springer Nature in Nature Medicine
- Vol. 14 (7) , 731-737
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke
TPA is a clot-buster used to treat stroke, but if it's given too late after stroke onset, it can cause complications like hemorrhage. Daniel Lawrence and his colleagues show that a US Food and Drug Administration–approved kinase inhibitor, Gleevec, can prevent this side effect, thereby extending tPA's therapeutic window. Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA be administered within 3 h of symptoms. Here we report that tPA activation of latent platelet-derived growth factor-CC (PDGF-CC) may explain these limitations. Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. In contrast, co-injection of neutralizing antibodies to PDGF-CC with tPA blocks this increased permeability, indicating that PDGF-CC is a downstream substrate of tPA within the neurovascular unit. These effects are mediated through activation of PDGF-α receptors (PDGFR-α) on perivascular astrocytes, and treatment of mice with the PDGFR-α antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. These data demonstrate that PDGF signaling regulates blood-brain barrier permeability and suggest potential new strategies for stroke treatment.
- 22 June 2008
- Published by Springer Nature in Nature Medicine
- Vol. 14 (7) , 731-737
Top Cited PapersActivation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke
TPA is a clot-buster used to treat stroke, but if it's given too late after stroke onset, it can cause complications like hemorrhage. Daniel Lawrence and his colleagues show that a US Food and Drug Administration–approved kinase inhibitor, Gleevec, can prevent this side effect, thereby extending tPA's therapeutic window. Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA be administered within 3 h of symptoms. Here we report that tPA activation of latent platelet-derived growth factor-CC (PDGF-CC) may explain these limitations. Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. In contrast, co-injection of neutralizing antibodies to PDGF-CC with tPA blocks this increased permeability, indicating that PDGF-CC is a downstream substrate of tPA within the neurovascular unit. These effects are mediated through activation of PDGF-α receptors (PDGFR-α) on perivascular astrocytes, and treatment of mice with the PDGFR-α antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. These data demonstrate that PDGF signaling regulates blood-brain barrier permeability and suggest potential new strategies for stroke treatment.
- 11 November 2005
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 97 (10) , 1036-1045
Platelet-Derived Growth Factor D Induces Cardiac Fibrosis and Proliferation of Vascular Smooth Muscle Cells in Heart-Specific Transgenic Mice
Platelet-derived growth factor (PDGF)-D is a member of the PDGF/vascular endothelial growth factor family that activates PDGF receptor β (PDGFR-β). We show that PDGF-D is highly expressed in the myocardium throughout development and adulthood, as well as by arterial vascular smooth muscle cells (vSMCs). To obtain further knowledge regarding the in vivo response to PDGF-D, we generated transgenic mice overexpressing the active core domain of PDGF-D in the heart. Transgenic PDGF-D stimulates proliferation of cardiac interstitial fibroblasts and arterial vSMCs. This results in cardiac fibrosis followed by dilated cardiomyopathy and subsequent cardiac failure. Transgenic mice also display vascular remodeling, including dilation of vessels, increased density of SMC-coated vessels, and proliferation of vSMCs, leading to a thickening of tunica media. The thickening of arterial walls is a unique feature of PDGF-D, because this is not seen when PDGF-C is overexpressed in the heart. These results show that PDGF-D, via PDGFR-β signaling, is a potent modulator of both vascular and connective tissue growth and may provide both paracrine and autocrine stimulation of PDGFR-β. Our data raise the possibility that this growth factor may be involved in cardiac fibrosis and atherosclerosis.
- 11 November 2005
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 97 (10) , 1036-1045
Platelet-Derived Growth Factor D Induces Cardiac Fibrosis and Proliferation of Vascular Smooth Muscle Cells in Heart-Specific Transgenic Mice
Platelet-derived growth factor (PDGF)-D is a member of the PDGF/vascular endothelial growth factor family that activates PDGF receptor β (PDGFR-β). We show that PDGF-D is highly expressed in the myocardium throughout development and adulthood, as well as by arterial vascular smooth muscle cells (vSMCs). To obtain further knowledge regarding the in vivo response to PDGF-D, we generated transgenic mice overexpressing the active core domain of PDGF-D in the heart. Transgenic PDGF-D stimulates proliferation of cardiac interstitial fibroblasts and arterial vSMCs. This results in cardiac fibrosis followed by dilated cardiomyopathy and subsequent cardiac failure. Transgenic mice also display vascular remodeling, including dilation of vessels, increased density of SMC-coated vessels, and proliferation of vSMCs, leading to a thickening of tunica media. The thickening of arterial walls is a unique feature of PDGF-D, because this is not seen when PDGF-C is overexpressed in the heart. These results show that PDGF-D, via PDGFR-β signaling, is a potent modulator of both vascular and connective tissue growth and may provide both paracrine and autocrine stimulation of PDGFR-β. Our data raise the possibility that this growth factor may be involved in cardiac fibrosis and atherosclerosis.
- 1 November 2005
- Published by Elsevier in Experimental Cell Research
- Vol. 310 (2) , 401-408
Development of a versatile reporter assay for studies of retinol uptake and metabolism in vivo
- 1 November 2005
- Published by Elsevier in Experimental Cell Research
- Vol. 310 (2) , 401-408
Development of a versatile reporter assay for studies of retinol uptake and metabolism in vivo
- Open Access
- 1 July 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (29) , 26856-26862
Structural Requirements for Activation of Latent Platelet-derived Growth Factor CC by Tissue Plasminogen Activator
- 1 July 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (29) , 26856-26862
Open AccessStructural Requirements for Activation of Latent Platelet-derived Growth Factor CC by Tissue Plasminogen Activator